3Basch E, Gabardi S, Ulbricht C. 2003. Bitter melon (Momordica charantia): a review of effieaey and safety [ J ]. American Journal of Health-system Pharmacy, 60(4): 356-359.
4Chaturvedi P. 2012. Antidiabetic Potentials of Momordica charantia: Multiple mechanisms behind the effects [ J]. Journal of Medicinal Food, 15(2): 101-107.
5Fang E F, Ng T B. 2011. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties[J]. Current Molecular Medicine, 11 (5) : 417-436.
6Hazarika R, Parida P, Neog B, Yadav R N S. 2012. Binding energy calculation of GSK-3 protein of human against some anti-diabetic compounds of Momordica charantia Linn (Bitter Melon)[J]. Bioinformation, 8(6): 251-254.
7Nerurkar P, Ray R B. 2010. Bitter melon: antagonist to cancer [J]. Pharmaceutical Research, 27(6): 1049-1053.
8Oishi Y, Sakamoto T, Udagawa H, Taniguchi H, Kobayashi- Hattori K, Ozawa Y, Takita T. 2007. Inhibition of increases in blood glucose and serum neutral fat by Momordica cbarantia Saponin fraction[J]. Bioscience, Biotechnology, and Biochemistry, 71(3): 735-740.
9Schaefer H, Renner S S. 2010. A three-genome phylogeny of momordica (Cucurbitaceae) suggests seven returns from dioecy to monoecy and recent long-distance dispersal to Asia[J]. Molecular Phylogenetics and Evolution, 54:553- 560.
10Senanayake G V K, Fukuda N, Nshizono S, Wang Y M, Nagao K, Yanagita T, Iwamoto M, Ohta H. 2012. Mechanisms underlying decreased hepatic triacylglycerol and cholesterol by dietary bitter melon extract in the rat[J]. Lipids, 47(5): 495-503.
